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We have previously reported that ostial in-stent restenotic lesions
treated with intracoronary radiation have equivalent clinical out-
comes to nonostial irradiated in-stent restenotic lesions and have
significantly reduced recurrent restenosis compared to in-stent
restenotic ostial lesions treated with conventional percutaneous
interevention alone (1). We did not find that postprocedural
minimal luminal diameter correlated with subsequent failure,
although smaller vessels (based on reference vessel diameter) have
higher restenosis rates. Intracoronary radiation therapy reduces
angiographic restenosis in all sized vessels, with the effect seen
predominantly in small vessels (2.5 mm) (2). In the current
analysis, these factors did not influence clinical outcomes.
The initial enthusiasm for the cutting balloon as an interven-
tional strategy for in-stent restenosis has not been supported by
reduced event rates in clinical trials. There is no evidence showing
the cutting balloon to be superior over conventional angioplasty
with adjunctive intracoronary radiation.
Our ongoing analysis suggests the time to first target vessel
revascularization in the majority of patients is between 6 to 12
months, suggesting there is a “delay” in recurrent restenosis
compared to conventional angioplasty. Recurrent restenosis be-
yond 12 months has been infrequent in the majority of published
Washington Radiation for In-stent restenosis Trial (WRIST)
series.
The overall use of glycoprotein (GP) IIb/IIIa inhibitors in the
current analysis was 22% and did not influence clinical outcomes.
Integrilin WRIST was a randomized trial addressing whether the
treatment of eptifibatide (small-molecule competitive GPIIb/IIIa
inhibitor) would improve both the procedural and the long-term
outcomes in patients undergoing treatment for in-stent restenosis
with intracoronary radiation therapy. That study (submitted for
publication) did not detect differences in major clinical events with
use of GPIIb/IIIa inhibitors. However, at any end point of the
study there was nonsignificant reduction of creatine phosphokinase
release in the eptifibatide group when compared to control, and
these findings may stimulate a larger study to detect benefit of
GPIIb/IIIa inhibitors in the setting of intracoronary radiation
therapy.
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Clinical Decision Making
on Statin Drug Interactions
Recent comments by Dr. Hansten (1) regarding drug-drug inter-
actions and myopathy risk with statins provide important addi-
tional information to guidelines issued last year on the use of these
agents (2). The metabolism of statins is complex, with extensive
conversion between the lactone, open-acid, and glucuronidated
forms as well as other less common metabolites (3,4). As Dr.
Hansten noted, pravastatin undergoes the least cytochrome P450
(CYP)-mediated metabolism and is therefore the least susceptible
to interactions with drugs that inhibit this system (5–7). Also,
simvastatin and lovastatin are more prone to interactions with
CYP inhibitors, owing in part to the fact that these agents are
administered as the more lipophilic lactone form, whereas all other
agents (including cerivastatin) are administered as the open-acid
form (3,8). And though these findings are important, I believe they
should be incorporated into clinical practice with several important
caveats in mind.
First, the kinetics of statins is more complex than just their
hepatic handling. The 5-fold increase in pravastatin area under the
curve (AUC) induced by cyclosporine is now widely recognized to
be the result of inhibition of the adenosine triphosphate-binding
cassette transporter P-glycoprotein (Pgp) in the gut wall (9,10).
Inhibition of Pgp allows greater absorption of pravastatin, thereby
increasing its systemic bioavailability, which is already four-fold
higher than lovastatin and simvastatin (3,8). Other inhibitors of
Pgp include erythromycin, quinidine, amiodarone, and verapamil
(11–13).
Second, the greatest risk of myopathy with statins occurs when
they are used with other lipid-lowering agents and is the result of
pharmacodynamic, as well as pharmacokinetic, interactions
(3,8,10,14). In this regard, pravastatin carries an increased risk
similar to the other agents (5,15,16). And though case reports of
myopathy are more common with lovastatin and simvastatin, four
published studies of 39,285 patients and over 160,000 patient-
years of therapy have failed to find a greater risk for these agents
compared to placebo (14,17,18).
Finally, the primary aim of statins is to reduce cardiovascular
(CV) events. The recent failure of 40 mg of pravastatin to
significantly reduce CV events in the ALLHAT-LLT trial (19)
stands in contrast to the recent findings of a robust benefit of 40
mg of simvastatin in the HPS trial (17). It is also notable that while
a lower threshold low density lipoprotein (LDL) of 125 mg/dl was
found for the beneficial effects of pravastatin in both the CARE
and LIPID trials (20,21), no such threshold finding for simvastatin
was found in the 4S trial (18). In fact, in the HPS trial, CV events
were significantly reduced by simvastatin in the 3,500 participants
with a baseline LDL below 100 mg/dl (mean 97 mg/dl) (17).
Thus, though interactions should always be considered when
prescribing multiple medications, until clearer mechanisms of both
benefit and risk are elucidated for statins, outcomes data remain
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crucial to clinical decision making with this important class of
drugs.
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I agree with Dr. Williams that simvastatin and lovastatin are more
prone than pravastatin to interact with drugs that inhibit cyto-
chrome P450 isozymes. But some of his other points do not survive
a careful reading of the scientific data.
First, Dr. Williams states that the interaction between prava-
statin and cyclosporine is “widely recognized” to involve
P-glycoprotein (PGP) and cites two references (1,2), but neither
study provides any scientific support for his claim. Indeed, the
limited available information suggests that pravastatin is a sub-
strate for other transporters such as canalicular multispecific
organic anion transporter (cMOAT) or organic anion-transporting
polypeptide (OATP) (3,4).
More importantly, even after years of frequent use of pravastatin
with cyclosporine, there is little evidence that the combination is
harmful (5–7), unlike lovastatin and simvastatin, where up to
20-fold increases in statin serum concentrations have been re-
ported and rhabdomyolysis has occurred (1,8–11). Moreover, even
if all statins were equally likely to interact with cyclosporine,
transplant patients receive other drugs as well, and the possibility
of the patient receiving other CYP3A4 inhibitors with lovastatin
or simvastatin creates additional concerns (10,11).
Dr. Williams further contends that myopathy following statin-
gemfibrozil combinations results from a pharmacodynamic inter-
action. This was commonly held, but we now know that gemfi-
brozil substantially increases serum concentrations of lovastatin
and simvastatin (12,13). Thus, the interaction is pharmacokinetic;
whether a simultaneous pharmacodynamic interaction exists is
speculative. Moreover, neither of the references Dr. Williams cited
to support myopathy following pravastatin-gemfibrozil contained
any actual cases of myopathy.
Dr. Williams cites large outcome trials, but such studies are
notoriously misleading in assessing drug interactions. For example,
the RALES trial found spironolactone plus angiotensin-
converting enzyme inhibitors safe and effective in treating severe
heart failure (14). Yet it is clear that in certain predisposed
patients—particularly those who get larger doses of spironolactone
in the presence of renal disease and diabetes—fatal hyperkalemia
can result (15–17). Thus it is with lovastatin and simvastatin where
life-threatening rhabdomyolysis has occasionally occurred owing to
drug interactions. The fact that serious or fatal drug interactions
are rare does not absolve us from preventing them when the
scientific evidence allows us to do so.
Finally, one can put statin drug interactions in the context of
what we have learned about drug interactions over the past 40
years. The poverty of proposing “class effects” for drug interactions
has been repeatedly confirmed, and it is extraordinarily rare for all
members of a drug class to interact homogeneously. Nonetheless,
it is convenient to say that we have insufficient information to be
certain that individual members of a drug class interact differently
from each other. If we held all drug interactions to that standard,
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